Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Sarah Atkinson’s research team investigates whether an iron export mutation in African populations can protect from anaemia, malaria and bacterial infections.

Control of iron metabolism is fundamental to almost all known life. Malaria parasites and other infectious pathogens require iron to grow and multiply, and the human host has evolved to withhold iron from these pathogens using iron-binding and chaperone transport proteins. One such protein is ferroportin, which transports iron from the inside to the outside of a cell. A mutation (Q248H) in ferroportin increases cellular iron export, leading to a 60% decrease in iron within the Q248H cells. The mutation has various outcomes depending on which cells it affects – for example, in red blood cells it might protect from excess toxic iron and haemolytic anaemia, while in enterocytes and macrophages, it might increase iron absorption and recycling.

Since the iron export mutation occurs primarily in populations of African ancestry, it has been hypothesized that the variant has been positively selected due to protection from malaria. However, a recent study conducted by Dr Sarah Atkinson, Senior Lecturer in the Department of Paediatrics and at the KEMRI-Wellcome Trust Research Programme in Kilifi Kenya, shows little evidence to support this claim. The research team used data from 18,320 children from across Africa and 380 pregnant women from The Gambia to determine what are some health impacts of the Q248H mutation. While the iron export mutation may protect from iron deficiency and anaemia, it does not prevent bloodstream bacterial infections. Additionally, there is little evidence that the mutation protects from malaria as it is unlikely to deprive malaria parasites of iron essential for their growth. Finally, Q248H does not appear to be evolutionary selected in African populations due to malaria exposure.

 

The research, published in Science Advances, is available at: https://advances.sciencemag.org/content/5/9/eaaw0109

Muriuki_aaw0109_image.png

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.

Study raises hope of pre-school type 1 diabetes screening programme

Researchers in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes before children develop symptoms or need insulin.

Angelman syndrome: first patient to receive potential therapy in Oxford

Things that seemed impossible, only a few years ago, are happening today. The first patient in Europe and one of the first in the world was injected with a potential treatment, GTX-102, in a phase I/II clinical trial in Oxford.

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Why it's so hard to treat pain in infants

For decades physicians believed that premature babies didn’t experience pain. Here’s what doctors know now – and the innovative solutions being embraced by today's caregivers.

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.